This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares in Q4; the quarter-end stake was valued at $192.59 million. The filing signals institutional accumulation but is a routine disclosure and likely only a modest, idiosyncratic influence on Apellis stock rather than a market-moving event.

Analysis

RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares in Q4; the quarter-end stake was valued at $192.59 million. The filing signals institutional accumulation but is a routine disclosure and likely only a modest, idiosyncratic influence on Apellis stock rather than a market-moving event.